Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma

Eligibility Criteria

• 1. Biopsy-confirmed diagnosis of squamous cell carcinoma of the head and neck
• 2. Subjects newly diagnosed with any T stage, any subsite within the head and neck that are scheduled to undergo surgical resection.
• 3. Subjects are to be staged clinically and radiographically node negative (cN0)
• 4. Planned standard of care surgery with curative intent for squamous cell carcinoma
• 5. Age \> 18 years
• 6. Have acceptable hematologic status, coagulation status (11 to 13.5 seconds. international normalized ratio (INR) of 0.8 to 1.1), kidney function, and liver function including the following clinical results:
• 1. Hemoglobin ≥ 9 gm/dL
• 2. White blood cell count ≥ 3000/mm3
• 3. Platelet count ≥ 100,000/mm3
• 4. Serum creatinine ≤ 1.5 times upper reference range
• 5. alanine transaminase (ALT) (SGPT) 7-56 units/liter, aspartate aminotransferase (AST) (SGOT) 5-40 units/liter.
• 1. Received an investigational drug within 30 days prior to the first dose of \[89Zr\]panitumumab.
• 2. Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment.
• 3. Previous HNSCC resection.
• 4. History of infusion reactions to monoclonal antibody therapies.
• 5. Pregnant or breast-feeding women.
• 6. Magnesium (\<1.7 mg/dL) or potassium (\<3.6 mmol/L) lower than the normal institutional values.
• 7. Subjects receiving Class I-A (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.
• 8. Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis.
• 9. Severe renal disease or anuria (Creatinine within normal institutional limits OR Creatinine clearance ≥60 mL/min/1.73 m2 for patients with creatinine levels).
• 10. Known hypersensitivity to panitumumab or any of its components.
• 11. Weight over 350 lbs., due to the scanner bore size.
• 12. Contraindication for MRI procedures (e.g. non-removable metal implants or certain tattoos).